Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition containing celecoxib and tramadol

A composition and pharmacy technology, applied in the field of tramadol's pharmacy composition, can solve the problems of poor pain relief and other problems, and achieve the effects of easy packaging, suitable for large-scale production, excellent hardness and interlayer adhesion

Inactive Publication Date: 2018-05-11
YOO YOUNG PHARM CO LTD
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, since this only indirectly suppresses pain through anti-inflammatory effects, it is not as effective as the above-mentioned opioid analgesics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition containing celecoxib and tramadol
  • Pharmaceutical composition containing celecoxib and tramadol
  • Pharmaceutical composition containing celecoxib and tramadol

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0080] Hereinafter, the present invention will be illustrated by way of examples. On the other hand, it should be noted that these examples do not limit the invention in any way.

[0081][Basic conditions]

[0082] The celecoxib used in this example is a raw material containing D90 of 10 to 15 μm and D50 of 4 to 7 μm.

[0083] "200 mg celecoxib capsules" and "100 mg tramadol hydrochloride (Tridol) sustained-release tablets" refer to single doses of celecoxib and tramadol on the market, respectively.

[0084] The approximate main components of the product names used in this Example are as follows.

[0085] Table 1

[0086]

[0087]

Embodiment 1

[0088] [Example 1] Formulation of insoluble drugs after compatibilization

[0089] Example 1-1) Formulation using water-soluble polymers, surfactants, and sugars—Confirmation of the dissolution form according to the ratio of water-soluble polymers and surfactants: using celecoxib and the following excipients, with The wet granule form was combined, dried, granulated, blended and purified and subjected to in vitro dissolution testing.

[0090] Table 2

[0091]

[0092] Only the celecoxib granules (granules) of Table 2 are filled in the capsules, and the dissolution evaluation is carried out. The results are as follows in Table 3 and figure 1 .

[0093] table 3

[0094]

[0095] Example 1-2) Formulation using water-soluble polymers, surfactants, and saccharides—confirmation of the dissolution form according to the amount of saccharides: Combine celecoxib and the following excipients in wet granule form Dried, granulated, blended and purified, and subjected to in vitro...

Embodiment 2

[0128] [Example 2] Sustained release of water-soluble drugs

[0129] YYC-301-1-(59+XX) in the following table refers to the bilayer tablet laminated with the celecoxib domain YYC-301-1-59 of Table 25 and the tramadol domain YYC-301-1-XX .

[0130] Example 2-1) Formulation using Ethylcellulose and wax-like lipid excipients—confirmation of poor dissolution form according to the amount of wax-like lipid excipients: using tramadol hydrochloride and the following excipients formulations, combined, dried, granulated, blended and purified in wet granule form, and subjected to in vitro dissolution testing.

[0131] Table 15

[0132]

[0133] The stripping evaluation result of table 15 is as follows table 16 and Figure 8 shown.

[0134] Table 16

[0135]

[0136] Example 2-2) Formulation using ethyl cellulose and wax-like lipid excipients—confirmation of poor dissolution morphology according to the amount of ethyl cellulose: using tramadol hydrochloride and the following ex...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a complex containing celecoxib and tramadol. The present invention is designed such that, even though two different active ingredients are prepared into a single dosage form, the release patterns of respective drugs are optimized in the expression of synergy effects, with respect to pain, of the respective drugs, through the new prescription.

Description

technical field [0001] The present invention relates to a pharmaceutical composition comprising celecoxib, known as a selective COX-2 inhibitor, and tramadol, as an opioid analgesic. Background technique [0002] [pain] [0003] According to the definition of the International Association for the Study of Pain, pain is an unpleasant sensory and emotional experience caused by actual or potential tissue damage. The causes of pain can be broadly divided into sensory conditions resulting from injury or inflammation of bodily or resistant tissues, and neuropathic conditions resulting from damage to nerves. Among them, the reported pathogenesis of the perceived condition is as follows. [0004] When tissue is damaged, the injury stimulus (stimulus) itself transmits pain by exciting myelin sheath (A-delta) and C-nociceptor (C-nociceptor). Subsequently, bradykinin, serotonin, K+, H+ and substance P are released from the damaged tissue cells and the end of the peripheral nerve. I...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/415A61K31/135A61K47/26A61K47/38A61K47/44
CPCA61K31/635A61K31/137A61K47/38A61K47/32A61K47/14A61K47/20A61K47/44A61K47/26A61P29/00A61K2300/00A61K47/36A61K31/135A61K31/415A61K9/209A61K31/133A61K31/18A61P25/04A61P43/00A61K9/4808A61K9/4866
Inventor 金正铸李东民金善庚
Owner YOO YOUNG PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com